The family of an ex-Catholic priest is reportedly taking Novartis to court after he allegedly suffered brain injury from participating in a clinical trial assessing Jakavi (ruxolitinib).
News
Welsh leukaemia patients win access to Ariad’s Iclusig
Wales will be the first place in the UK where patients with two rare forms of leukaemia will have access to Ariad Pharmaceutical’s Iclusig (ponatinib) on the National Health Service.
Europe clears BI’s Ofev for lung-scarring disease IPF
The European Commission has approved Boehringer Ingelheim’s Ofev (nintedanib) to treat the lung-scarring disease idiopathic pulmonary fibrosis, providing patients with a new treatment option.
European green light for Novartis’ Cosentyx in psoriasis
Novartis’ Cosentyx (secukinumab) has become the first IL-17 inhibitor to win European approval for first-line treatment of moderate-to-severe psoriasis.
Global biomedical research spending: US falling, China rising
New research shows that the US’s global leadership role for spending on biomedical research and health service innovation is eroding, and that China’s spending in these areas is increasing dramatically.
Govt plan to eradicate TB from England
NHS England and Public Health England are investing £11.5 million in a new initiative aimed at eliminating tuberculosis from England by 2020.
FDA green light for AbbVie’s PD drug Duopa
US regulators issued a green light last week for a new Parkinson’s disease treatment designed to help better control motor fluctuations in patients with advanced disease.
J&J Ebola consortia gets 100m euros to accelerate vaccine
Johnson & Johnson has set up a new research powerhouse to accelerate work on its experimental Ebola vaccine, underpinned by an external grant totalling 100 million Euros.
£1 billion to make GP premises fit for purpose
NHS England has unveiled funding of £1 billion over the next four years to improve GP premises.
Bone Therapeutics IPO to raise up to 25 million euros
Belgian cell therapy specialist Bone Therapeutics has unveiled plans for an initial public offering on European stock markets which it hopes will raise 20-25 million euros.
Celgene’s Otezla gets Europe OK for psoriasis and PsA
Regulators in Europe have given the green light to Celgene Corp’s pill Otezla for psoriasis and psoriatic arthritis.
Europe approves AbbVie multi-pill regimen for HCV
Less than a month after getting the green light in the USA, AbbVie has secured approval in Europe for its all-oral, interferon-free
NHS England rounds on critics as care.data relaunches
As it relaunches the controversial care.data initiative, NHS England has responded vigorously to contest fresh media reports over patient confidentiality concerns.
NICE merges GP care and commissioning committees
The National Institute for Health and Care Excellence is streamlining two of its committees which focus on improving the quality of care provided by doctors and supporting the NHS in commissioning better quality healthcare.
NICE nods for Janssen, Gilead hep C drugs
The National Institute for Health and Care Excellence has issued new draft guidelines expanding its endorsement of Janssen’s Olysio (simeprevir) and Gilead’s Sovaldi (sofosbuvir) to treat certain patients with hepatitis C on the National Health Service in England.
